CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease

CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease

Abstract Background Efavirenz is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is a CNS-specific enzyme that metabolizes cholesterol to 24-hydroxycholesterol (24HC). We have previously shown that allosteric CYP46A1 activation by low-dose efavirenz in a transgenic mouse model of Alzheimer’s di...

Full description

Bibliographic Details
Main Authors: Alan J. Lerner, Steven E. Arnold, Erin Maxfield, Aaron Koenig, Maria E. Toth, Brooke Fortin, Natalia Mast, Bianca A. Trombetta, John Denker, Andrew A. Pieper, Curtis Tatsuoka, Sangeetha Raghupathy, Irina A. Pikuleva
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Alzheimer’s Research & Therapy
Subjects:
CYP46A1
Efavirenz
Alzheimer’s disease
24-Hydroxycholesterol
Stable isotope labeling kinetics
Online Access:https://doi.org/10.1186/s13195-022-01151-z

Similar Items

Similar Items